Literature DB >> 10419462

HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines.

D J Dairaghi1, R A Fan, B E McMaster, M R Hanley, T J Schall.   

Abstract

Uncertainty regarding viral chemokine function is mirrored by an incomplete knowledge of host chemokine receptor usage by the virally encoded proteins. One such molecule is vMIP-I, a C-C type chemokine of undefined function and binding specificity, encoded by the Kaposi's sarcoma herpesvirus HHV-8. We report here that vMIP-I binds to and induces cytosolic [Ca(2+)] signals in human T cells selectively through CCR8, a CC chemokine receptor associated with Th2 lymphocytes. Furthermore, using a panel of 65 different human, viral, and rodent chemokines, we have established a comprehensive ligand binding "fingerprint" for CCR8. The receptor exhibits marked "high" affinity (K(d) < 15 nM) only for four chemokines, three of them of viral origin: vMIP-I, vMIP-II, vMCC-I, and human I-309. A previously unreported second class of lower affinity ligands includes MCP-3 and possibly two other viral chemokines. vMIP-I and I-309 appear to act as CCR8 agonists: binding to and inducing cytosolic [Ca(2+)] elevation through the receptor. By contrast, vMIP-II and vMCC-I act as potent antagonists: binding without inducing signaling, and blocking the effects of I-309 and vMIP-I. These results suggest a ligand hierarchy for CCR8, identifying vMIP-I as a selective viral chemokine agonist. CCR8 may thus engage a specific subset of chemokines with the potential to regulate each other during viral infection and immune regulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419462     DOI: 10.1074/jbc.274.31.21569

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Evolutionary aspects of oncogenic herpesviruses.

Authors:  J Nicholas
Journal:  Mol Pathol       Date:  2000-10

Review 2.  Molecular machinations: chemokine signals in host-pathogen interactions.

Authors:  S W Chensue
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 3.  Cytokine homologs of human gammaherpesviruses.

Authors:  Sang-Hoon Sin; Dirk P Dittmer
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

4.  Human herpesvirus 8-encoded cytokines.

Authors:  John Nicholas
Journal:  Future Virol       Date:  2010-03       Impact factor: 1.831

Review 5.  Immune evasion by Kaposi's sarcoma-associated herpesvirus.

Authors:  Hye-Ra Lee; Stacy Lee; Preet M Chaudhary; Parkash Gill; Jae U Jung
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

Review 6.  Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.

Authors:  Emily Cousins; John Nicholas
Journal:  Recent Results Cancer Res       Date:  2014

7.  The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist.

Authors:  Hans R Lüttichau
Journal:  J Biol Chem       Date:  2009-12-31       Impact factor: 5.157

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects.

Authors:  C Liu; Y Okruzhnov; H Li; J Nicholas
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Negative elongation factor-mediated suppression of RNA polymerase II elongation of Kaposi's sarcoma-associated herpesvirus lytic gene expression.

Authors:  Zsolt Toth; Kevin F Brulois; Lai-Yee Wong; Hye-Ra Lee; Brian Chung; Jae U Jung
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.